Non-nucleoside adenosine deaminase inhibitors: 2000 – 2004

Bibliography

• RUDOLPHI KA, SCHUBERT P, PARKINSON FE, FREDHOLM BB: Neuroprotective role of adenosine in cerebral ischemia. Trends. Pharmacol. Sci. (1992) 13:439–445.
   PubMed Web of Science ®Google Scholar
• CRONSTEIN BN: Adenosine, An endogenous antiinflammatory agent. Appl. PhysioL (1994) 76:5–13.
   PubMed Web of Science ®Google Scholar
• OHTA A, SITKOVSKY M: Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature (2001) 414:916–920.
   PubMed Web of Science ®Google Scholar
• NAKAZAWA T, KOSHIBA M, KOSAKA H et al.: Adenosine downregulates cytokine-induced expression of intercellular adhesion molecule-1 on rheumatoid synovial fibroblasts independently of adenosine receptor signaling. Drug Dev. Res. (2003) 58:368–376.
   Google Scholar
• MARQUARDT DL, GRUBER HE, WASSERMAN SI: Adenosine release from stimulated mast-cells. Proc. Natl. Acad. Sci. USA (1984) 81:6192–6196.
   PubMed Web of Science ®Google Scholar
• FILIPPINI A, TAFFS RE, SITKOVSKY MV: Extracellular ATP in T-lymphocyte activation: possible role in effector functions. Proc. Natl. Acad. Sci. USA (1990) 87:8267–8271.
   PubMed Web of Science ®Google Scholar
• CRONSTEIN BN, NAIME D, OSTAD E: The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J. Clin. Invest. (1993) 92:2675–2682.
   Google Scholar
• CRONSTEIN BN, MONTESINOS MC,WEISSMANN G: Sites of action for future therapy: an adenosine-dependent mechanism by which aspirin retains its antiinflammatory activity in cyclooxygenase-2 and NF-KB knockout mice. Osteoarthr. CartiL (1999) 7:361–363.
   PubMed Web of Science ®Google Scholar
• CRONSTEIN BN, MONTESINOS MC,WEISSMANN G: Salycylates and sulfasalazine but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFkB. Proc. Natl. Acad. Sci. USA (1999) 96:6377–6381.
   PubMed Web of Science ®Google Scholar
• RESTA R, THOMPSON LF: SCID: the role of adenosine deaminase deficiency. Immunol. Today (1997) 18:371–374.
   Google Scholar
• GIBLETT ER, ANDERSON JE, COHEN F, POLLARA B, MEUWISSEN HJ: Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet (1972) 2:1067–1069.
   PubMed Web of Science ®Google Scholar
• HIRSCHHORN R, PAPAGEORGIOU PS, KESARWALA HH, TAFT LT: Amelioration of neurologic abnormalities after 'enzyme replacement' in adenosine deaminase deficiency. N Engl. J. Med. (1980) 303:377–380.
   PubMed Web of Science ®Google Scholar
• VALENZUELA A, BLANCO J, CALLEBAUT C et al.: Adenosine deaminase binding to human CD26 is inhibited by HIV-1 envelope glycoprotein gp120 and viral particles. J. ImmunoL (1997) 158:3721–3729.
   PubMed Web of Science ®Google Scholar
• DELIA S, MASTROIANNI CM, MASSETTI AP et al.: Adenosine deaminase activity and acquired immunodeficiency syndrome (AIDS). Clin. Chem. (1987) 33:1675.
   Google Scholar
• NAKAMACHI Y, KOSHIBA M, NAKAZAWA T et al.: Specific increase in enzymatic activity of adenosine deaminase 1 in rheumatoid synovial fibroblasts. Arthr. Rheum. (2003) 48:668–674.
   Google Scholar
• YUKSEL H, AKOGLU TFJ: Serum and synovial fluid adenosine deaminase activity in patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis. Ann. Rheum. Dis. (1988) 47:492–495.
   Google Scholar
• VALENTINE WN, PAGLIA DE, TARTAGLIA AP, GILSANZ F: Hereditary hemolytic anemia with increased red cell adenosine deaminase (45- to 70-fold) and decreased adenosine triphosphate. Science (1977) 195:783–785.
   PubMed Web of Science ®Google Scholar
• SMITH JF, POPLACK DG, HOLTMAN BJ, LEVENTHAL BG, YARBRO G: Correlation of adenosine deaminase activity with cell surface markers in acute lymphoblastic leukemia. J. Clin. Invest. (1978) 62:710–712.
   Google Scholar
• SIMPKINS H, STANTON A. DAVIS BH: Adenosine deaminase activity in lymphoid subpopulations and leukemias. Cancer Res. (1981) 41:3107–3110.
   Google Scholar
• KAMEOKA J, TANAKA T, NOJIMA Y, SCHLOSSMAN SF, MORIMOTO C: Direct association of adenosine deaminase with T cell activation antigen, CD26. Science (1993) 261:466–469.
   PubMed Web of Science ®Google Scholar
• FRANCO R, VALENZUELA A, LLUIS C, BLANCO J: Enzymatic and extraenzymatic role of ecto-adenosine deaminase in lymphocytes. ImmunoL Rev. (1998) 161:27–42.
   PubMed Web of Science ®Google Scholar
• MORIMOTO C, SCHLOSSMAN SF: The structure and function of CD26 in the T-cell immune response. ImmunoL Rev. (1988) 161:55–70.
   Google Scholar
• VAN DER WEYDEN MB, KELLY WN: Human adenosine deaminase. Distribution and properties. J. Biol. Chem. (1976) 251:5448–5456.
   Google Scholar
• HIRSCHHORN R, RATECH H: Isozyme of adenosine deaminase. In: Isoqmes: Current Topics in Biological and Medical Research (Volume 4). Liss AR (Ed.), NY, USA (1980):131–157.
   Google Scholar
• KURATA N: Adenosine deaminase. Jpn. Clin. Med. (1995) 53:122–127.
   Google Scholar
• RATECH H, HIRSCHHORN R: Serum adenosine deaminase in normals and in a patient with adenosine deaminase deficient-severe combined immunodeficiency. Clin. Chim. Acta. (1981) 115:341–347.
   PubMedGoogle Scholar
• NIEDZWICKI JG, ABERNETHY DR: Structure-activity relationship of ligands of human plasma adenosine deaminase2. Biochem. PharmacoL (1991) 41:1615–1624.
   Google Scholar
• WIGINTON DA, ADRIAN GS, HUTTON JJ: Sequence of human adenosine deaminase cDNA including the coding region and a small intron. Nucleic Acid Res. (1984) 12:2439–2446.
   PubMed Web of Science ®Google Scholar
• WIGINTON DA, KAPLAN DJ, STATES JC et al.: Complete sequence and structure of the gene for human adenosine deaminase. Biochemistry (1986) 25:8234–8244.
   PubMed Web of Science ®Google Scholar
• YEUNG CY, INGOLIA DE, ROT DB et al.: Identification of functional murine adenosine deaminase cDNA clones by complementation in Escherichia coli. J. Biol. Chem. (1985) 260:10299–10307.
   PubMedGoogle Scholar
• AL-UBAIDI MR, RAMAMURTHY V, MAA MC et al.: Structural and functional analysis of the murine adenosine deaminase gene. Genomics. (1990) 7:476–485.
   PubMedGoogle Scholar
• KELLY MA, VESTLING MM, MURPHY CM et al.: Primary structure of bovine adenosine deaminase. j Pharm. Biomed. Anal. (1996) 14:1513–1519.
   PubMedGoogle Scholar
• WILSON DK, RUDOLPH FB, QUIOCHO FA: Atomic structure of adenosine deaminase complexed with a transition-state analog: understanding catalysis and immunodeficiency mutations. Science (1991) 252:1278–1284.
   PubMed Web of Science ®Google Scholar
• •First paper describing the crystal structure of murine ADA.
   Google Scholar
• WILSON DK, QUIOCHO FA: A pre-transition-state of an enzyme: X-ray structure of adenosine deaminase with bound 1-deazaadenosine and zinc-activated water. Biochemistry (1993) 32: 1689-1694.
   Google Scholar
• SHARFF AJ, WILSON DK, CHANG Z, QUIOCHO FA: Refined 2.5 A structure of murine adenosine deaminase at pH 6.0. Mo/. Bid. (1992) 226:917–921.
   Google Scholar
• SIDERAKI V, MOHAMEDALI KA, WILSON DK et al.: Probing the functional role of two conserved active site asparates in mouse adenosine deaminase. Biochemistry (1996) 35:7862–7872.
   PubMed Web of Science ®Google Scholar
• SIDERAKI V WILSON DK, KURZ LC, QUIOCHO FA, RUDOLF FB: Site-directed mutagenesis of histicline 238 in mouse adenosine deaminase: substitution of histidine 238 does not impede hydroxylate formation. Biochemistry (1996) 35:15019–15028.
   Google Scholar
• WANG Z, QUIOCHO FA: Complexes of adenosine deaminase with two potent inhibitors: X-ray structures in four independent molecules at pH of maximum activity. Biochemistry (1998) 37:8314–8324.
   PubMed Web of Science ®Google Scholar
• KINOSHITA T. NISHIO N, SATO A et al.: Crystallization and preliminary analysis of bovine adenosine deaminase. Acta. Crystallogr. (1999) D55:2031–2032.
   Google Scholar
• KINOSHITA T. NISHIO N, NAKANISHI I et al.: Crystal structure of bovine adenosine deaminase complexed with 6-hydroxyl-1,6-dihydropurine riboside. Acta. Crystallogr. (2003) D59:299–303.
   Google Scholar
• •First paper describing the crystal structure of bovine ADA.
   Google Scholar
• TERASAKA T, KINOSHITA T, KUNO M, NAKANISHI I: A highly potent non-nucleoside adenosine deaminase inhibitor: Efficient drug discovery by intentional lead hybridization./ Am. Chem. Soc. (2004) 126:34–35.
   PubMed Web of Science ®Google Scholar
• ••First paper describing ADA crystalstructures complexed with non-nucleoside ADA inhibitors and inhibitor-induced conformational change.
   Google Scholar
• RAFEL M, CERVANTES F, BELTRAN JM et al.: Deoxycoformycin in the treatment of patients with hairy cell leukemia. Cancer (2000), 88:352–357.
   PubMed Web of Science ®Google Scholar
• HONMA Y: A novel therapeutic strategy against monocytic leukemia with deoxyadenosine analogs and adenosine deaminase inhibitors. Leuk. Lymph. (2001) 42:953–962.
   PubMed Web of Science ®Google Scholar
• HUSSAIN K, MAZZA JJ, CLOUSE LH:Tumor lysis syndrome (TLS) following fludarabine therapy for chronic lymphocytic leukemia (CLL): case report and review of the literature. Am. J. HematoL (2003) 72:212–215.
   PubMed Web of Science ®Google Scholar
• TOFOVIC SP, KUSAKA H, LI P, JACKSON EK: Effects of adenosine deaminase inhibition on blood pressure in old spontaneously hypertensive rats. Clin. Exp. Hyperten. (1998) 20:329–344.
   PubMed Web of Science ®Google Scholar
• TIAN YH, SCHAFER T, SCKELL A, SCHILLING MK: Adenosine deaminase inhibition attenuates reperfusion low flow and improves graft survival after rat liver transplantation 1. Transplantation (2000) 69:2277–2281.
   PubMed Web of Science ®Google Scholar
• SUPERGEN, INC.: American Society of Hematology Annual Meeting. SD, USA (6 Dec, 2004).
   Google Scholar
• ADAIN S, YALOVETSKIY IV, NARDULLI BA et aL: Inhibiting adenosine deaminase modulates the systemic inflammatory response syndrome in endotoxemia and sepsis. Am. J. PhysioL Regul. Integ. Comp. PhysioL (2002) 282:R1324–R1332.
   Google Scholar
• CRISTALLI G, COSTANZI S, LAMBERTUCCI C et al.: Adenosine deaminase: functional implications and different classes of inhibitors. Med. Res. Rev. (2001) 21:105-128. Good recent comprehensive review ofADA and inhibitors.
   Google Scholar
• MCCONNELL WR, FURNER RL, HILL DL: Pharmacokinetics of 2'-deoxycoformycin in normal and L1210 leukemic mice. Drug Metab. Dispos. (1979) 7:11–13.
   PubMed Web of Science ®Google Scholar
• LATHIA C, FLEMING GF, MEYER M, RATAIN MJ, WHITFIELD L: Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment. Cancer Chemother. PharmacoL (2002) 50:121–126.
   PubMed Web of Science ®Google Scholar
• MCCONNELL WR, EL-DAREER SM, HILL DL: Metabolism and disposition of erythro-9-(2-hydroxy-3-nonyl)['4C] adenine in the rhesus monkey. Drug Metab. Dispos. (1980) 8:5–7.
   PubMed Web of Science ®Google Scholar
• LAMBE CU, NELSON DJ: Pharmacokinetics of inhibition of adenosine deaminase by erythro-9-(2-hydroxy-3-nonyl) adenine in CBA mice. Biochem. PharmacoL (1982) 31:535–539.
   PubMed Web of Science ®Google Scholar
• BROGDEN RN, SORKIN EM: Pentostatin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders. Drugs (1993) 46:652–677.
   Google Scholar
• TERASAKA T, NAKANISHI I, NAKAMURA K et al.: Structure-based de novo design of non-nucleoside adenosine deaminase inhibitors. Bioorg. Med. Chem. Lett. (2003) 13:1115–1118.
   Google Scholar
• SAWA T, FUKAGAWA Y, HOMMA I, TAKEUCHI T, UMEZAWA H: Mode of inhibition of coformycin on adenosine deaminase. J. Antibiot. (1967) 20:227–231.
   PubMed Web of Science ®Google Scholar
• WOO PWK, DION HW, LANGE SM, DAHL LF, DURHAM LJ: A novel adenosine and Ara-A deaminase inhibitor, (R)-3-(2'-deoxy-B-D-erythro-pentofuranosyl)-3,6,7,8- tetrahydroimidazo [4,5-d] [1,3] diazepin-8-ol. J. Heterocyd Chem. (1974) 11:641–643.
   Google Scholar
• KODAMA K, KUSAKABE H, MACHIDA H et al.: Isolation of 2'-deoxycoformycin and cordycepin from wheat bran culture of Aspergillus nidulans Y176-2. Agric. Biol. Chem. (1979) 43:2357–2377.
   Google Scholar
• SUPERGEN, INC.: Press release (31/03/2003)
   Google Scholar
• SUPERGEN, INC.: Press release (09/07/2003)
   Google Scholar
• PADUA RA, GEIGER JD, DELANEY SM, NAGY JI: Rat brain adenosine deaminase after 2'-deoxycoformycin administration: Biochemical properties and evidence for reduced enzyme levels detected by 2'- [3H]deoxycoformycin ligand binding. J. Neurochem. (1992) 58:421–429.
   Google Scholar
• SIAW MF, COLEMAN MS: In vitro metabolism of deoxycoformycin in human T lymphoid cells. J. Biol. Chem. (1984) 259:9426–9433.
   PubMed Web of Science ®Google Scholar
• RAFEL M, CERVANTES F, BELTRAN JM et al.: Deoxycoformycin in the treatment of patients with hairy cell leukemia. Cancer (2000) 88:352–357.
   PubMed Web of Science ®Google Scholar
• CRISTALLI G, ELEUTERI A. VITTORI S, VOLPINI R, CAMAIONI E, LUPIDI G: Adenosine deaminase inhibitors: structure-activity relationship in 1-deazaadenosine and erythro-9-(2-hydroxy-3-nonyfiadenine analogues. Drug Dev. Res. (1993) 28:253–258.
   Web of Science ®Google Scholar
• SCHAEFFER HJ, SCHWENDER CF: Enzyme inhibitors. 26. Bridging hydrophobic and hydrophilic regions on adenosine deaminase with some 9-(2-hydroxy-3-alkyfiadenines. J. Med. Chem. (1974) 17:6–8.
   Google Scholar
• BAKER DC, HANVEY JC, HAWKINS LD, MURPHY J: Identification of the bioactive enantiomer of erythro-3-(adenine-9-y1)-2-nonanol (EHNA), a semi-tight binding inhibitor of adenosine deaminase. Biochem. PharmacoL (1981) 30:1159–1160.
   PubMed Web of Science ®Google Scholar
• BESSODES M, BASTIAN G, ABUSHANAB E et aL: Effect of chirality in erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) on adenosine deaminase inhibition. Biochem. PharmacoL (1982) 31:879–882.
   Google Scholar
• PRAGNACHARYULU PV, VARKHEDKAR V, CURTIS MA, CHANG IF, ABUSHANAB E: Adenosine deaminase inhibitors. Synthesis and biological evaluation of unsaturated, aromatic, and oxo derivatives of (+)-erythro-9-(2'S-hydroxy-3'R-nonypadenine [(+)-EHNA]. J. Med. Chem. (2000) 43:4694–4700.
   Google Scholar
• VOLPINI R, CAMAIONI E, LUPIDI G, VITTORI S, CRISTALLI G: Adenosine deaminase inhibitors: diastereoisomeric resolution and biological activity of 1-(2-hydroxy-3-nonyl) 1,2,4-triazole 3-carboxamide. Farmaco (1997) 52:429–433.
   PubMedGoogle Scholar
• TERASAKA T, KINOSHITA T, KUNO M, SEKI N, TANAKA K, NAKANISHI I: Structure-based design, synthesis, and structure-activity relationship studies of novel non-nucleoside adenosine deaminase inhibitors. J. Med. Chem. (2004) 47:3730–3743.
   PubMedGoogle Scholar
• LIPINSKI CA, LOMBARDO F, DOMINY BW, FEENEY PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deli v. Rev. (1997) 23:3–25.
   Web of Science ®Google Scholar
• TERASAKA T, OKUMURA H, TSUJI K et aL: Structure-based design and synthesis of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors. J. Med. Chem. (2004) 47:2728–2731.
   PubMed Web of Science ®Google Scholar